We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00679692
First Posted: May 19, 2008
Last Update Posted: May 19, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kaohsiung Medical University Chung-Ho Memorial Hospital
  Purpose

BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and human growth hormone (HGH) in the progression of chronic liver disease remain to be elucidated and investigated.

METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.


Condition
Hepatitis Liver Cirrhosis Hepatocellular Carcinoma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications.

Resource links provided by NLM:


Further study details as provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:

Biospecimen Retention:   Samples Without DNA
serum

Enrollment: 210
Study Start Date: September 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
3:
three arms for study

Detailed Description:
healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Acute hepatitis liver cirrhosis hepatocellular carcinoma
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Hepatocellular carcinoma
  • Must be primary Hepatocellular carcinoma and untreament

Exclusion Criteria:

  • treatment Hepatocellular carcinoma
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00679692


Locations
Taiwan
Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road
Kaohsiung, Taiwan
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Investigators
Principal Investigator: chiou m Lin, Ms Kaohsiung Medical University
  More Information

Responsible Party: Kaoshing Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier: NCT00679692     History of Changes
Other Study ID Numbers: KMUH-IRB-950123
First Submitted: May 15, 2008
First Posted: May 19, 2008
Last Update Posted: May 19, 2008
Last Verified: January 2006

Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
GH,IGF-1, IGFBP-3

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Diseases
Liver Cirrhosis
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action